Polling Questions

< All Questions
 The Phase 3 bremelanotide trials reflect the efficacy and safety of the medication
 If approved by the FDA, bremelanotide offers women and clinicians an alternative, non-hormonal, on demand medication for the treatment of Hypoactive Sexual Desire Disorder
 Hypoactive Sexual Desire Disorder remains a distressing condition for many women and their partners
 All of the above

Your answers are confidential and will be used for educational purposes only.